Treatment of Localized Dedifferentiated Liposarcoma in the Extremity or Trunk

Dedifferentiated liposarcoma (DDLPS) arising in the extremity or trunk follows a treatment framework comparable to other soft tissue sarcomas at these sites, with limb preservation as the central surgical objective.

Clinical Scenario

This protocol addresses patients with localized dedifferentiated liposarcoma confined to the extremity or trunk. In this anatomical setting, limb-sparing surgery is considered the standard of care, with the goal of achieving adequate oncologic margins while preserving limb function.

Treatment Approach

Management is built around limb-sparing oncologic resection of the DDLPS with oncologically sound surgical margins. For high-grade tumors, radiation therapy — delivered either before or after surgery — is an important component of local control. In patients considered to be at elevated risk for recurrence, perioperative chemotherapy may also be part of the approach.

Complete resection strategy, radiation timing and dosing, patient selection criteria, and chemotherapy regimen details are available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DDLPS of the ET is treated with a similar approach to most soft tissue sarcomas of ET.
In the extremity, limb-sparing surgery is considered the standard of care.
Radical resection of the DDLPS with 1–2 cm of normal muscle is required, with sparing of critical structures such as major nerves or blood vessels, unless directly invaded.
For deep tumors, the periosteum can be resected as a margin using a periosteal elevator to spare the need for bone resection.
Radiation therapy should be considered, either preoperatively or postoperatively, for a high-grade DDLPS of the extremity, given improvement in local control when combined with limb-sparing surgery.
Despite limited data, perioperative chemotherapy with an anthracycline in combination with ifosfamide, for example, may be considered for patients with DDLPS at high risk for recurrence.

DOI: 10.1016/j.ctrv.2024.102846

View source ↗